Key Takeaways
- TARGAN has entered into a $100 million financing agreement with Symbiotic Capital to accelerate the deployment of its poultry technologies.
- The deal, closed in late 2025, included an initial funded tranche of $30 million to strengthen the company’s balance sheet.
- Proceeds will support the commercial scaling of WingScan™, a high-speed avian sex identification system.
- TARGAN reported doubling its revenue from 2024 to 2025, with further significant growth projected for the 2026 fiscal year.
Strategic Capital Infusion for TARGAN
TARGAN, a prominent animal health and AgTech firm, has finalized a $100 million credit facility with Symbiotic Capital, a private credit fund focused on the healthcare and life sciences sectors. This financing replaces the company's previous senior lender and provides the liquidity necessary to support an aggressive commercial roadmap. The capital is designated for scaling global operations and preparing a new wave of technologies for market entry throughout 2026 and 2027.
Scaling WingScan™ Technology Globally
The primary driver for this investment is the global momentum of WingScan™, TARGAN’s flagship automated system. The technology utilizes artificial intelligence and high-speed imaging to identify the gender of chicks, a process historically performed manually. By automating this stage of production, the system allows hatcheries to handle up to 160,000 chicks per hour with over 98% accuracy. This efficiency enables gender-specific rearing strategies that improve uniformity and performance across the poultry value chain.
Commercial Growth and Market Expansion
TARGAN has experienced a period of rapid financial expansion, with year-over-year revenue doubling into 2025. The company is currently expanding its footprint across the United States, Europe, and South America. The new funding will allow TARGAN to invest in regional service infrastructure and increased manufacturing capacity to meet the rising demand for precision automation in animal protein production.
Leadership Perspectives on Innovation
Ramin Karimpour, CEO and Founder of TARGAN, emphasized that the financing aligns with the company's mission to solve global food production challenges.
“We are entering a period of extraordinary growth, and this financing enhances our ability to deliver technologies that address some of the most pressing challenges in global food production,” said Karimpour. “I’m looking forward to scaling our operations and investing in the infrastructure that will support the next wave of technologies.”
Chris York, Senior Managing Director at Symbiotic Capital, noted the company's role as a pioneer in the sector: “TARGAN has established itself as a true pioneer in the animal health space, bringing automation, precision, and data-driven decision-making to the animal protein production industry at scale. We are pleased to support TARGAN in this next phase of expansion.”
TARGAN Future Outlook for 2026 and 2027
With a strengthened balance sheet, TARGAN is positioned to transition from a focused technology provider to a broad-scale infrastructure partner for the global poultry industry. The company remains focused on delivering data-driven tools that enhance animal welfare by reducing handling time while simultaneously increasing the operational margins for large-scale producers.
